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Abstract
 
Using an expression gene trapping strategy, we recently identified a novel gene, hematopoietic
zinc finger (
 
Hzf
 
), which encodes a protein containing three C
 
2
 
H
 
2
 
-type zinc fingers that is pre-
dominantly expressed in megakaryocytes. Here, we have examined the in vivo function of 
 
Hzf
 
by gene targeting and demonstrated that 
 
Hzf
 
 is essential for megakaryopoiesis and hemostasis in
vivo. 
 
Hzf
 
-deficient mice exhibited a pronounced tendency to rebleed and had reduced 
 
 
 
-gran-
ule substances in both megakaryocytes and platelets. These mice also had large, faintly stained
platelets, whereas the numbers of both megakaryocytes and platelets were normal. These results
indicate that 
 
Hzf
 
 plays important roles in regulating the synthesis of 
 
 
 
-granule substances and/
or their packing into 
 
 
 
-granules during the process of megakaryopoiesis.
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Introduction
 
During hematopoiesis, anucleate platelets are generated
from megakaryocytes and have an essential role in main-
taining hemostasis in vivo. During megakaryocyte differen-
tiation, megakaryocyte-restricted progenitor cells commence
an unusual process, terminal endomitosis, in which DNA
replication occurs but neither the nucleus nor the cell un-
dergoes division (1). Hence, mature megakaryocytes are in-
variably polyploid, containing 4N to 64N of the normal
diploid amount of DNA (2). Because platelets can produce
only limited amounts of proteins, their cytoplasmic struc-
tures, including characteristic granules, are mostly derived
from megakaryocytes (3). Morphologically, four distinct
categories of granules differing in their internal constituents
are produced by maturing megakaryocytes: 
 
 
 
-granules,
dense granules, lysosomal granules, and microperoxisomal
granules (3). The 
 
 
 
-granules, which are the most numer-
ous, contain various proteins, including platelet-derived
growth factor (PDGF)
 
*
 
, platelet factor 4, and von Wille-
brand factor (vWF). These proteins are synthesized in
megakaryocytes and then transported to 
 
 
 
-granules. These
packed 
 
 
 
-granules are subsequently shed from megakaryo-
cytes (4). Thus, the process of megakaryocyte differentia-
tion involves a complex series of cellular processes that cul-
minate in the generation of functionally mature platelets.
Genetic approaches involving gene targeting in mice
have revealed several genes and their protein products that
are essential for megakaryopoiesis. These include various
transcription factors, such as p45 NF-E2 (5), 
 
maf
 
G (6),
GATA-1 (7), and 
 
Fli
 
-1 (8). The transcription factor NF-E2
is a heterodimer of two proteins, p45 and p18, that are
members of the Cap’n’Collar protein and Maf subfamilies,
respectively (9, 10). Deficiency of the p45 NF-E2 gene
blocks completion of megakaryopoiesis and results in the
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complete absence of platelets (5), whereas the absence of
MafG leads to hyperproliferation of megakaryocytes and
mild thrombocytopenia (6). Mice carrying megakaryocyte-
specific deletion of the GATA-1 zinc finger protein exhibit
severely impaired cytoplasmic maturation of megakaryo-
cytes and reduced platelet numbers (7). Mice carrying a
null mutation in 
 
Fli
 
-1, a member of the 
 
ETS
 
 family of
winged helix-turn-helix transcription factors, exhibit a
block in megakaryocyte differentiation (8).
The process of megakaryocyte differentiation also re-
quires the interaction between thrombopoietin (TPO), also
known as megakaryocyte growth and development factor
(MGDF), and its cognate receptor c-Mpl (11–18). The
ligand TPO/MGDF increases megakaryocyte ploidy at low
concentrations while the final stage of platelet release is not
dependent on TPO/MGDF (19). c-
 
mpl
 
–deficient mice ex-
hibit thrombocytopenia and impaired megakaryopoiesis
(20, 21). In addition, TPO/MGDF null mutant mice have
decreased number of both platelets and megakaryocyte
progenitors, and lower ploidy levels of megakaryocytes
(22). Interestingly, both c-Mpl and TPO/MGDF null mice
do not exhibit a bleeding disorder, suggesting that platelets
produced from the abnormal megakaryocytes in these mice
can function normally.
Using an approach that we have termed ‘expression gene
trapping,’ we have previously identified and mutated in
embryonic stem (ES) cells a number of genes that are ex-
pressed in hematopoietic and/or endothelial cells in vitro
and in vivo (23, 24). One of these genes, hematopoietic
zinc finger (
 
Hzf
 
), encodes a novel zinc finger protein
which is predominantly expressed in megakaryocytes (24).
Mice homozygous for the gene trapped allele of 
 
Hzf
 
(
 
Hzf
 
gt
 
/
 
gt
 
) exhibit no obvious phenotype (24). Transcripts cor-
responding to the 
 
Hzf
 
 gene were detected in 
 
Hzf
 
gt
 
/
 
gt
 
 mice,
consistent with the possibility that the trapped 
 
Hzf
 
 allele
generated in our previous study was not a null allele.
Therefore, to investigate the in vivo role of 
 
Hzf
 
, we gener-
ated mice with a null 
 
Hzf
 
 mutation by gene targeting. Here
we describe the essential function of 
 
Hzf
 
 in 
 
 
 
-granule for-
mation and megakaryopoiesis.
 
Materials and Methods
 
Generation of Hzf
 
 
 
/
 
 
 
 Mutant Mice.
 
DNA fragments corre-
sponding to the murine 
 
Hzf
 
 gene fragments were cloned from a
129/Sv genomic DNA library using a mouse 
 
Hzf
 
 cDNA probe
(24). 17 overlapping phage genomic clones containing exons en-
coding three zinc finger domains were isolated. A targeting vec-
tor was designed to replace a 5.5-kb genomic fragment including
the exons encoding three zinc finger domains with an internal ri-
bosome-entry site (IRES) 
 
Lac
 
Z and a neomycin resistant gene
(
 
neo
 
). IRES 
 
Lac
 
Z and 
 
neo
 
 were inserted in the pPNT targeting
vector in the sense orientation to 
 
Hzf
 
 transcription, such that
IRES 
 
Lac
 
Z was flanked on the 3
 
 
 
 side by 1.6 kb of genomic
DNA and that 
 
neo
 
 was flanked on the 5
 
 
 
 side by 4.5 kb of ge-
nomic DNA. The targeting vector was linearized with 
 
Not
 
I and
electroporated into R1 ES cells. After positive-negative selection
with gancyclovir and G418, 800 surviving clones were picked
and screened by Southern blot analysis. Three out of six homolo-
gous recombinant ES clones were aggregated into CD1 blas-
tomeres and transferred to foster mothers to generate chimeras.
Chimeric mice were mated with CD1 females, and germline
transmission of the mutant allele was verified by PCR and South-
ern blot analysis of ear punched tissues and tail DNA from F1 off-
spring. A primer “a” and “b” specific for the 
 
Hzf
 
 gene (5
 
 
 
-
GGACCCTGTACAGAAAGCTGT-3
 
 
 
 and 5
 
 
 
-GCTTGGTC-
TACAGAGTGATT-3
 
 
 
, respectively) and a primer “c” specific
for the IRES gene (5
 
 
 
-GGAGGGAGAGGGGCGGAATT-3
 
 
 
)
were used in PCR analysis. Germline transmission of the targeted
 
Hzf
 
 allele was achieved for three independent ES clones. F2 off-
spring from heterozygous intercrosses were genotyped by South-
ern blotting. Mutant mice derived from three targeted ES cells
showed the identical phenotype.
 
Histological Analysis.
 
Organs were isolated in ice-cold PBS 3
wk after birth, fixed overnight in 4% paraformaldehyde at 4
 
 
 
C
(for brains, fixed at least 1 wk in 4% paraformaldehyde at 4
 
 
 
C),
dehydrated, and embedded in paraffin. Sections 5-
 
 
 
m thick were
cut and stained with hematoxylin and eosin.
 
Hematological Analysis.
 
4-wk-old mice were anesthetized with
methoxyflurane. Peripheral blood was collected by heparinized
capillary puncture of the retroorbital venous plexus into a tube
containing 5 
 
 
 
l of 0.5 M EDTA, pH 8.0 (Becton Dickinson).
Peripheral blood cell counts were determined with MASCOT
automated hematology system (CDC Technologies). Blood
smears and bone marrow smears were stained with Wright-
Giemsa stain.
The preparation of platelets was performed essentially as de-
scribed previously (25). Peripheral blood, which was prepared as
described above, was centrifuged at 300
 
 
 
 
 
g
 
 for 10 min at room
temperature to obtain platelet-rich plasma. The platelets were
washed three times with PBS by centrifugation at 1,300
 
 
 
 
 
g
 
 for 10
min and were used immediately for Western immunoblot analysis.
 
Bleeding Time Assays.
 
Bleeding times were measured as de-
scribed previously (26, 27) using 4-wk-old mice. 2 mm of the tip
at the tail was cut with a sharp scalpel blade, the tail was placed
in a solution of saline at 37
 
 
 
C, and the time for the flow of blood
to cease was recorded. Genotyping of the animals took place af-
ter this procedure so that tails were intact for bleeding-time mea-
surements. If bleeding restarted within 1 min, this result was re-
corded as a rebleed and taken to indicate an unstable hemostatic
event.
 
Measurements of Megakaryocyte Frequency and DNA Content.
 
DNA distribution of megakaryocytes in unfractionated bone
marrow cells was determined as described previously (2, 28).
Bone marrow cells were harvested from 
 
Hzf
 
 mutant and control
mice.
 
CFU-Mk Assay.
 
Megakaryocyte progenitor cells, in the bone
marrow from 
 
Hzf
 
 mutant and control mice, were assayed in col-
lagen-based media (StemCell Technologies) supplemented with
recombinant human TPO (50 ng/ml), IL-6 (20 ng/ml), IL-11
(50 ng/ml), and recombinant mouse IL-3 (10 ng/ml). Colonies
were stained for acetylcholinesterase (AChE) activity counted af-
ter 6 d incubation.
 
Ultrastructural Studies.
 
Freshly excised spleens obtained from
3–5-wk-old 
 
Hzf
 
 
 
/
 
 
 
 and control mice were fixed in 2% glutaral-
dehyde (Canemco, Inc.) in 0.1 M sodium cacodylate buffer, pH
7.3, (Canemco, Inc.). Samples were washed with 0.1 M sodium
cacodylate buffer, pH 7.3, postfixed with 1% osmium tetroxide in
0.1 M sodium cacodylate buffer, pH 7.3, dehydrated in graded
ethanols, and embedded in spurr epoxy resin (Canemco, Inc.).
Embedded tissues were sectioned with an RMC 6000 ultrami-
crotome, (RMC-EM), stained with uranyl acetate, lead citrate, 
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and examined in a Philips CM 100 electron microscope (Philips
Electron Optics).
For platelet analysis, blood was collected into a syringe with
prewarmed 2% glutaraldehyde (Canemco, Inc.) in 0.1 M sodium
cacodylate buffer, pH 7.3 (Canemco, Inc.), from the inferior
vena cava of anesthetized mice. Immediately, the syringe was in-
verted several times and was set at room temperature for 2 h.
Platelet-rich plasma was prepared as described above and then an-
alyzed, as described previously (29).
For quantitative estimation of vacant 
 
 
 
-granules in platelets,
dense and vacant 
 
 
 
-granules were counted in platelets from 
 
Hzf
 
 
 
/
 
 
 
and 
 
 
 
/
 
 
 
 mice by observers blinded to the experiment. The
frequency of vacant 
 
 
 
-granules was calculated from the number of
detected vacant 
 
 
 
-granules divided by that of dense 
 
 
 
-granules.
To estimate the levels of PDGF-A in megakaryocytes, freshly
excised spleens obtained from 3–5-wk-old 
 
Hzf
 
 
 
/
 
 
 
 and control
mice were fixed in 0.1 M sodium cacodylate buffer, pH 7.3 con-
taining a combination of 0.1% glutaraldehyde (Canemco, Inc.)
and 4% paraformaldehyde (Canemco, Inc.). The samples were
washed with the same buffer, dehydrated with graded ethanol,
infiltrated in lowicryl (Canemco, Inc.), and polymerized under
UV at –20
 
 
 
C overnight. The sections were rinsed with PBS con-
taining 0.15% glycine and 0.5% BSA, washed with 0.5% BSA in
PBS, and then reacted with anti–PDGF-A antibody (Santa Cruz
Biotechnology, Inc.) for 1 h at 22
 
 
 
C. After washing with 0.5%
BSA in PBS, the sections were treated with anti–rabbit IgG con-
jugated with 10-nm gold (Amersham Pharmacia Biotech). After
washing with 0.5% BSA in PBS, PBS, and H
 
2
 
O, the sections
were stained with uranyl acetate, lead citrate, and examined in
the Philips CM 100 electron microscope. Then, PDGF-A label-
ing by counting the gold particles was determined as described
previously (30). Briefly, the field (3.35 
 
 
 
 2.7 
 
 
 
m
 
2
 
) from the im-
munogold stained sections were determined with a minimum of
10 high power field counted per mouse. The frequency of
PDGF-A gold particles in 
 
 -granules was calculated from the
number of detected gold particles in  -granules divided by that in
the whole field.
Western Blot Analysis. Bone marrow cells were isolated from
4-wk-old Hzf /  and Hzf /  mice, after washed with PBS, and
subsequently suspended in lysis buffer (25). Soluble fractions from
each sample were boiled with sample buffer for SDS-PAGE.
Eluted proteins were separated by electrophoresis and transferred
to nitrocellulose membranes (Schleicher & Schuell). Immuno-
blotting was performed as described previously (25). We evalu-
ated AChE expression to ensure equivalent sample loading.
Commercially available Abs to vWF (Dako), fibrinogen (ICN
Biochemicals), PDGF-A (Santa Cruz Biotechnology, Inc.),
PDGF-B (Santa Cruz Biotechnology, Inc.), and AChE (Santa
Cruz Biotechnology, Inc.) were used at the concentrations of 57
 g/ml, 160  g/ml, 5  g/ml, 5  g/ml, and 5  g/ml, respec-
tively. Goat anti–rabbit IgG Ab-conjugated with HRP and don-
key anti–goat IgG Ab conjugated with HRP were purchased
from Bio-Rad Laboratories and Santa Cruz Biotechnology, Inc.,
respectively. The signals were visualized with an enhanced
chemiluminescence detection system (Amersham Pharmacia Bio-
tech) as directed by the manufacturer.
The detection of platelet proteins was performed basically as
described previously (25). Briefly, washed platelets were lysed
with the same lysis buffer, as described above. Whole platelets
were treated with standard sample buffer and loaded onto 10%
SDS-PAGE following the same protocol as described above. We
evaluated glycoprotein (GP)IIb to ensure equivalent platelet pro-
tein loading. The anti–mouse GPIIb mAb and anti–rat IgG Ab
conjugated with HRP were purchased from BD PharMingen and
Santa Cruz Biotechnology, Inc., respectively. The anti-GPIIb
mAb and the anti–rat IgG Ab conjugated with HRP were used at
the concentrations of 0.25  g/ml and 0.8  g/ml, respectively.
The signal-enhancement was performed as described above.
RT-PCR Analysis. Bone marrow cells, from male Hzf / 
and Hzf /  mice, were used for RNA extraction and cDNA
synthesis, as described previously (31). The detailed method for
RT-PCR and the primer sequences were described elsewhere (5,
32). We equalized cDNAs from male Hzf /  and Hzf /  bone
marrow cells by RT-PCR of hypoxanthine phosphoribosyl
transferase. The RT-PCR products were analyzed by PAGE.
Statistical Analysis. Data were analyzed by using Student’s t
test. Values of P   0.05 were considered statistically significant.
All experiments were performed at least three times.
Results
Generation of Hzf /  Mutant Mice. The  Hzf gene was
disrupted in murine ES cells using a targeting vector in
which the exons encoding three zinc finger motifs were
deleted (Materials and Methods, and Fig. 1 A). The target-
ing vector was electroporated into R1 ES cells. After posi-
tive-negative selection and genotyping by Southern blot
analysis as described in Materials and Methods, six indepen-
dent clones were identified as heterozygous for the targeted
mutation at the Hzf locus. Three out of the six heterozy-
gous mutant ES clones were used to generate chimeric
mice. Chimeras were backcrossed to CD1 mice to generate
mice heterozygous for the Hzf mutation. Heterozygous
Hzf /  mice were fertile and were intercrossed to generate
homozygous Hzf /  mice (Fig. 1 B). The null mutation of
Hzf was confirmed by the absence of Hzf expression, as de-
termined by Northern blot analysis of RNA extracted from
brains of Hzf mutant mice at 3 wk after birth (Fig. 1 C).
Hemorrhage and Neonatal Lethality of Hzf /  Mice. Ini-
tial examination of the progeny from Hzf /  parents re-
vealed a reduced frequency of Hzf /  mice at 3 wk of age.
To determine the stage of neonatal development affected
by the Hzf mutation, neonatal genotyping was performed.
Of 300 offspring derived from heterozygous matings, 1-wk-
old Hzf /  pups were viable, usually of normal size,
and were present in the expected Mendelian frequency.
However, thereafter, especially between 2–3 wk after
birth, the percentage of homozygotes decreased (Table I).
As shown in Fig. 2 A, the size of 4-wk-old Hzf /  mice
were clearly distinguishable from their wild-type litter-
mates. Moreover, there was marked internal hemorrhaging
evident primarily in the brains and gastrointestinal tracts
(Fig. 2 B, and data not shown) in mutant neonates. This
hemorrhaging was the likely cause of neonatal lethality.
The surviving Hzf /  mice of either sex were fertile (data
not shown).
Unstable Hemostatic Plug Formation and Abnormal Platelet
Morphology in Hzf /  Mice. To determine whether the
hemorrhaging phenotype was related to defective hemosta-
sis in Hzf-deficient mice, we compared the bleeding times
and rebleeding occurrences of Hzf / , Hzf / , and Hzf / 
mice. There were no significant differences in bleeding944 The Essential Function of Hzf in  -Granule Formation and Megakaryopoiesis
times when Hzf /  mice were compared with wild-type
and  Hzf /  heterozygous mice (Fig. 3 A). However,
Hzf /  mice rebled after transient hemostasis relative to
the rebleeding frequency in wild-type and Hzf /  mice
(Fig. 3 B). These results indicate that Hzf-deficiency leads
to unstable hemostatic plug formation in vivo.
The defects in hemostasis in Hzf /  mice led us to ana-
lyze hematologic parameters in Hzf /  mice. Surprisingly,
complete hematologic profiles revealed no significant dif-
ferences in platelet counts and differential counts between
Hzf /  mice and their control littermates (data not
shown).
To address the defect of hemostasis in detail, we next ex-
amined the morphology of blood cells in peripheral blood
smears from Hzf /  mice. Normal platelet sizes from con-
trol mice were observed by comparison with the diameter
of erythrocytes (Fig. 3 C). Large faint-colored platelets
were occasionally observed in blood smears from Hzf / 
mice (Fig. 3 D). Although the frequency of these pale
ghostlike platelets was low, they were never observed in
peripheral blood smears from Hzf /  mice. To examine
these morphological differences more closely, we per-
formed ultrastructural analysis of peripheral platelets from
Hzf /  and control mice. As shown in Fig. 3 E, platelets
from wild-type mice had easily identified dense  -granules.
In contrast, Hzf /  platelets had significantly reduced
numbers of  -granules, with many vacuoles (Fig. 3 F; va-
cant frequency of  -granules, 9.4   15.4 [controls] vs. 80.6  
12.3 [Hzf / ], n   11, P   0.0001).
Numerous procoagulant substances are packed in platelet
 -granules, and the release of granule contents is important
for platelet function (33). vWF, one of the procoagulant
substances contained in platelet  -granules, is associated
Figure 1. Targeted disruption of
the Hzf locus. (A) A portion of the
mouse 129/Sv Hzf wild-type locus
(top) showing exons (open boxes)
and a 6.5-kb PstI fragment in the
wild-type allele. The targeting vec-
tor (middle) was designed to replace
exons encoding three zinc finger do-
mains with an IRES LacZ (closed
box) and a neo (hatched box). The
mutated Hzf locus (bottom) contains
a 4.5-kb PstI fragment. The posi-
tions of the 5  flanking and 3  flank-
ing probes used for Southern blot
analysis are shown. Positions of
PCR primers for the wild-type allele
(a and b) and the mutant allele (c)
are also shown. P, Ks, RI, Kp, C, X,
and B represent PstI, KspI, EcoRI,
KpnI, ClaI, XhoI, and BamHI sites,
respectively. (B) Genomic DNA was
isolated from Hzf / , Hzf / , and
Hzf /  mice, digested with PstI and
analyzed by Southern blot analysis.
Wild-type (6.5-kb) and mutant (4.5-
kb) bands are indicated. (C) North-
ern blot analysis of Hzf expression.
Total RNA extracted from the brains
(40  g per lane) was analyzed for the
expression of transcripts correspond-
ing to the Hzf gene.
Table I. Genotype Analysis of the Progeny from Hzf 
Heterozygous Intercrosses
Number of mice of each genotype Percentage
Stage +/+ +/   /  Total  / 
%
1 wk 10 22 12  44 27
2 wk 6 22 8 36 22
3 wk 32 90 24 146 16
4 wk 16 27 10 53 19
Total 295
Breeding pairs were set up between Hzf+/  males and females (129  
CD1 mixed background). Tails of newborn and weaning pups were
collected at the time of 1, 2, 3, and 4 wk after birth. The genotypes were
determined by PCR analyses, as described in Materials and Methods.
Each genotyping was confirmed by Southern blot analyses.945 Kimura et al.
with attachment of platelets onto damaged blood vessels,
thereby reinforcing the stability of the plug, and activating
the coagulation pathway that leads to blood clot formation
(33). To investigate whether  -granules in Hzf /  platelets
contain   -granule substances, we examined the protein
levels of platelet-vWF, a key GP involved in coagulation.
As shown in Fig. 3 G, the levels of vWF were dramatically
reduced in Hzf /  platelets compared with that observed
in platelets from wild-type mice.
Number and DNA Ploidy Levels of Megakaryocytes and
Megakaryocyte Progenitors from Hzf /  Mice. To explore in
greater detail the nature of the platelet defects described
above, we characterized megakaryocytes from Hzf /  mu-
tant mice. No differences in the numbers of megakaryo-
cytes were observed in the spleens and bone marrows of
Hzf mutant mice, as determined morphologically and by
flow cytometric analysis (Fig. 4 A–E).
Megakaryocyte development initiates with proliferation
of precursor cells. These precursor cells then undergo en-
domitosis, followed by cytoplasmic maturation and organi-
zation, culminating in platelet release (1). To determine
whether the process of endomitosis was affected by the ab-
sence of Hzf, we performed DNA ploidy analysis on bone
marrow megakaryocytes. As shown in Fig. 4 F, no signifi-
cant differences in DNA ploidy patterns were observed be-
tween wild-type, heterozygous, and homozygous mutant
mice. We next examined the levels of megakaryocyte pro-
genitor cells (CFU-Mk) in the bone marrow of Hzf wild-
type and mutant mice by plating bone marrow cells in
semi-solid media in the presence of TPO/MGDF. Normal
numbers of megakaryocyte progenitors were observed in
Hzf-deficient mice (data not shown).
Ultrastructural Analysis of Megakaryocytic Abnormality. To
characterize further the maturation defect in Hzf / 
mice, we performed electron microscopic analysis of
megakaryocytes derived from Hzf /  mice. As expected,
megakaryocytes from both Hzf /  and Hzf /  mice ex-
hibited hyperlobulated nuclei (Fig. 5 A and B). Megakaryo-
cytes  from  Hzf /  mice exhibited well-formed platelet
fields, demarcation membrane systems, and numerous
 -granules (Fig. 5 C); in contrast, Hzf /  megakaryocytes
displayed a dramatic reduction in the number of  -gran-
ules, with many vacuoles in their cytoplasm (Fig. 5 D).
Furthermore, detailed ultrastructural analysis revealed that
 -granules in megakaryocytes from control mice were
dense, readily identifiable, and exhibited distinct zones:
dense nucleoid regions and diffuse granular matrixes (Fig.
5 E). In contrast, the  -granules in Hzf /  megakaryo-
cytes were pale and vacant, although membranes of  -gran-
ules could be identified (Fig. 5 F). In addition, the ma-
jority of Hzf /    -granules were devoid of diffuse
granular matrixes, although dense nucleoid regions were
observed only in some  -granules in Hzf /  megakaryo-
cytes (Fig. 5 F).
Taken together, these data suggest that the process of en-
domitosis is not affected by Hzf-deficiency. However, Hzf-
deficiency appears to block the process of terminal matura-
tion of megakaryocytes, affecting the assembly of  -granule
substances in  -granules of megakaryocytes.
Reduced Concentrations of  -Granule Substances in Hzf / 
Megakaryocytes. Previous biochemical and immunoelec-
tron microscopic analyses have shown that megakaryo-
cytic  -granules contain numerous substances essential to
the coagulation system (3). To examine the effect of Hzf-
Figure 2. Growth retardation and hemorrhage in Hzf /  mice. (A) A Hzf /  mouse compared with a control littermate 4 wk after birth, demonstrat-
ing slightly smaller size. (B) Transverse section of the brain of a 3-wk-old Hzf /  mouse, demonstrating extensive hemorrhage. Original magnification:
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Figure 3. Unstable plug formation and abnormal plate-
let morphology in Hzf /  mice. (A) Time taken for ini-
tial cessation of bleeding. Each symbol represents a single
animal (Hzf /  mice, open squares, n    22; Hzf / 
mice, closed triangles, n    41; Hzf /  mice, closed
squares, n   19). Bars indicate the average bleeding time
for each genotype (Hzf /  mice, 177.0 s; Hzf /  mice,
162.8 s; Hzf /  mice, 290.5 s). Box and whisker graphs
indicate the median, first and third quartiles, and the total
range of bleeding times for each genotype. (B) Rebleed-
ing occurrences in Hzf /  (white column), Hzf /  (gray
column), and Hzf /  (black column) mice. Rebleeding
occurred in 68.4% of Hzf /  mice (n   19) as compared
with 36.4% (n   22) of Hzf /  and 36.6% (n   41) of
Hzf /  mice. (C) Peripheral blood smear from Hzf / 
mice demonstrates a normal platelet (arrowhead). Original
magnification:   100. (D) Peripheral blood smear from
Hzf /  mice reveals a large, faintly stained platelet. Rep-
resentative platelet is highlighted by an arrowhead. Origi-
nal magnification:  100. (E) Ultrastructural morphology
of platelets of peripheral blood from two individual Hzf / 
mice demonstrates normal  -granules. Scale bars, 500 nm.
(F) Ultrastructural analysis of abnormal platelet morphol-
ogy in Hzf /  mice. Platelets from two individual Hzf / 
mouse exhibit numerous vacuoles with reduced  -gran-
ules. Scale bars, 500 nm. (G) Reduced platelet-vWF in
Hzf /  mice. Whole washed-platelets from control lit-
termates and Hzf mutant mice were used to assay protein
levels of vWF. Hzf /  platelets have reduced protein lev-
els of vWF. GPIIb, which is a GP bound to plasma mem-
branes of platelets, was used to verify equivalent sample
loading. Molecular size markers are indicated on the left
in kilodaltons. This data was representative with compa-
rable results.947 Kimura et al.
Figure 4. The presence of mega-
karyocytes and normal aspects of
megakaryocyte maturation in
Hzf /  mice. (A and B) Transverse
sections through the spleens from
Hzf /  (A) and Hzf /  (B) mice,
demonstrating the presence of
megakaryocytes in each. A and B,
original magnification:  100. (C
and D) Microscopic examination of
bone marrow smears from Hzf / 
(C) and Hzf /  (D) mice, showing
the presence of megakaryocytes in
each. C and D, original magnifica-
tion:   100. (E) Flow cytometric
analysis confirms no significant
difference of megakaryocyte fre-
quency between control and Hzf / 
mice. The proportion of megakary-
ocytes to bone marrow cells was
performed after staining with 4A5
mAb, to murine megakaryocytes.
Six mice, which were age- and sex-
matched, were analyzed in each ge-
notype with FACScan™. Results
are presented as the means  SD.
(F) Representative megakaryocyte
DNA ploidy in Hzf /  mice. The
proportion of cells in each ploidy
class was determined by PI-staining
after gated on 4A5-positive cells
with FACScan™, demonstrating no effect of Hzf deficiency on endomitosis. Six mice, which were age- and sex-matched, were analyzed in each
genotype. This data was representative with comparable results.948 The Essential Function of Hzf in  -Granule Formation and Megakaryopoiesis
deficiency on production of  -granule substances in
megakaryocytes, we analyzed the levels of vWF, fibrino-
gen, PGDF-A, and PDGF-B by Western immunoblot-
ting. As shown in Fig. 6 A, the levels of adhesive GP,
vWF and fibrinogen, were both dramatically reduced in
Hzf /  bone marrow. In addition, Hzf-deficient bone
marrow had significantly decreased protein levels of
PDGF-A and PDGF-B.
To examine further the effect of Hzf deficiency on the
levels of  -granule substances in megakaryocytes, we per-
formed immunogold labeling followed by transmission
electron microscopy. Using this strategy, we observed con-
centrated gold particles corresponding to PDGF-A in
 -granules and on vesicles in the cytoplasm of Hzf / 
megakaryocytes (Fig. 6 B; numbers of PDGF-A gold parti-
cles in Hzf /   -granules: 19.8   5.7%, n   5). In con-
trast, PDGF-A was not detected in  -granules from Hzf / 
megakaryocytes although a few gold particles were present
on vesicles (Fig. 6 C; PDGF-A gold particles in Hzf / 
 -granules: 0.8   1.8%, n   5, P   0.001).
Transcript Levels of Megakaryocyte-specific Genes. To de-
termine whether the structural defects observed in mega-
karyocytes from Hzf /  mice were the consequence of an
earlier block in megakaryocyte maturation, we examined
the expression of two genes associated with megakaryo-
poiesis (29). In this experiment, bone marrow cells from
mutant and wild-type male mice were used as the source of
mRNAs for comparison of expression levels of the coadhe-
sive GP, vWF, and the cell surface receptor, GPIIb. As
shown in Fig. 7, Hzf /  megakaryocytes expressed an
equivalent level of RNA transcripts corresponding to
GPIIb as Hzf /  cells. In contrast, transcripts correspond-
ing to vWF gene were significantly reduced in Hzf /  cells
relative to that observed in wild-type cells.
Discussion
We have previously identified a novel gene, Hzf, by a
gene trapping strategy in ES cells (24). Hzf encodes a
novel protein containing three C2H2-type zinc fingers
and is predominantly expressed in megakaryocytes within
the hematopoietic system. In this study, we have investi-
gated the in vivo role of Hzf in mice using gene target-
ing. Hzf deficiency causes a block in the formation of
Figure 5. Ultrastructural analysis of megakaryo-
cytic abnormality. (A and B) Mature megakaryo-
cytes from the bone marrow of both Hzf /  (A)
and Hzf /  (B) mice exhibit hyperlobulated nuclei.
A and B, scale bars, 5,000 nm. (C) Detail of the cy-
toplasm of the megakaryocyte shown in A. Platelet
fields or territories are clearly demarcated. Many
 -granules are observed. N, nuclei. Scale bar, 2,500
nm. (D) Detail of the cytoplasm of the megakaryo-
cyte shown in B. The Hzf /  megakaryocyte re-
veals reduced numbers of  -granules, with many
vacuoles. N, nucleus. Scale bar, 2,500 nm. (E) Ul-
trastructural analysis of  -granules of the megakary-
ocyte from Hzf /  mice. Normal dense  -gran-
ules, which exhibits distinct zones: dense nucleoid
regions and diffuse granular matrixes are observed.
Scale bar, 500 nm. (F) Ultrastructural analysis of
 -granules of the megakaryocytes from Hzf / 
mice. Some vacuoles (arrowheads) and low dense
 -granules (arrows) are present in cytoplasm. M,
mitochondria, in which cristae are observed. Scale
bar, 500 nm.949 Kimura et al.
 -granules in megakaryocytes, abnormal platelet mor-
phology, and disruption of hemostasis in vivo. These
findings identify Hzf as a novel regulator of megakary-
opoiesis and hemostasis.
Megakaryocyte Development and  -Granule Formation in
Hzf-deficient Mice. Megakaryocytes in Hzf /  mice were
produced in normal number and appeared to undergo
complete differentiation based on DNA ploidy analysis.
Figure 6. Reduced concentrations of  -granule substances in megakaryocytes from Hzf /  mice. (A) Western immunoblotting analysis reveals re-
duced levels of vWF, fibrinogen, PDGF-A, and PDGF-B from bone marrow cells in Hzf /  mice. The AChE, a house keeping protein expressed spe-
cifically in megakaryoctes, was used to verify equivalent sample loading. This data was representative with comparable results. (B and C) Immunogold lo-
calization of PDGF-A on thin sections of megakaryocytes in the spleens of Hzf / (B) and Hzf /  (C) mice. (B) Concentrated gold particles are located
in the  -granules (arrowheads) and vesicles (arrows) of cytoplasm in megakaryocytes from Hzf /  mice. Scale bar, 500 nm. (C) A few gold particles are
present on the vesicles (arrows) of cytoplasm in megakaryocytes from Hzf /  mice. Partially empty  -granules and vacant  -granules are also observed.
Scale bar, 500 nm.950 The Essential Function of Hzf in  -Granule Formation and Megakaryopoiesis
Electronmicroscopic analysis revealed the presence of poly-
ploid nuclei and the characteristic demarcation membrane
system in megakaryocytes lacking HZF. Together, these
findings suggest that Hzf-deficiency does not cause a block
in the intermediate and late stages of megakaryocyte differ-
entiation. The numbers of megakaryocyte progenitor cells
were also not affected by the absence of Hzf, suggesting
that Hzf is not essential for the early stages of megakaryo-
cyte differentiation.
The electronmicroscopic and biochemical analyses re-
vealed that platelets and megakaryocytes from Hzf / 
mice contain numerous vacuoles with reduced amount of
 -granule substances. Interestingly, membranes of  -gran-
ules were observed in Hzf /  megakaryocytes. In addi-
tion, PDGF-A was not detected in the  -granules of
Hzf /  megakaryocytes although a few gold particles were
present on vesicles. Interestingly, immunoelectron micro-
scopic analysis shows that vWF is detected on small vesi-
cles of human cultured megakaryocytes (34). These find-
ings suggest that Hzf is required for the synthesis of
 -granule substances and/or the trafficking of these sub-
stances into  -granule bags during the process of mega-
karyocyte maturation.
Hzf in Platelet Morphogenesis and Hemostasis. Most Hzf / 
mice were smaller than their wild-type littermates, presum-
ably as a result of sustained hemorrhage during a period of
rapid growth. Because the numbers of platelets in Hzf mu-
tant mice were within normal range, HZF does not appear
to impair the release of platelets from megakaryocytes.
Nevertheless, circulating large, faintly stained platelets con-
taining numerous empty vacuoles were present in the pe-
ripheral blood of Hzf /  mice.
Platelets from Hzf /  mice have dramatically reduced
levels of the coadhesive GPs, vWF and fibrinogen. vWF
and fibrinogen contribute to hemostasis by producing a
platelet plug and then reinforcing the plug by converting
fibrinogen to fibrin strands, inducing activation of the co-
agulation pathway (33, 35). It is also known that GPIb,
which is a heterodimer of GPIb  and GPIb , has an im-
portant role in the adherence of platelets to subendothelial
surfaces with binding to vWF (35–37). Indeed, vWF / 
platelets exhibit delayed adhesion to vessel walls and they
failed to form thromba in arterioles in vivo (38, 39). Thus,
the instability of plug formation in Hzf-deficient mice may
result from a failure of platelet adhesion onto damaged
blood vessel walls, a process which is mediated by the bind-
ing of vWF to GPIb.
Gray Platelet Syndrome and Hzf Deficiency. It is of inter-
est to note that the phenotype of the Hzf /  mice de-
scribed here resembles that observed in patients with gray
platelet syndrome (GPS), a human congenital bleeding dis-
order (40, 41). Platelets from patients with GPS appear
gray and are markedly deficient in morphologically dense
 -granules and in the  -granule substances,  -thrombo-
globulin, fibrinogen, vWF, and PDGF (42–45). These sim-
ilarities raise the intriguing possibility that GPS may be as-
sociated with defects in the biochemical pathway defined
by HZF.
Gene Regulation by Hzf. The generation of mice with
targeted mutations in specific genes has greatly enhanced
our understanding of megakaryocyte differentiation. RNA
transcripts for the vWF gene were significantly reduced in
bone marrow cells derived from Hzf /  mice. Thus, these
results suggest either that Hzf directly regulates the expres-
sion of vwf and/or that delayed or incomplete maturation
of megakaryocytes as a result of Hzf deficiency is reflected
in decreased expression levels of vwf transcripts.
Taken together, this data suggests that Hzf plays an es-
sential role in hemostasis in vivo through its direct or indi-
rect regulation of the levels of at least one molecule, vWF
known to be involved in plug formation through the adhe-
sion of platelets to endothelial cells. We conclude that the
defects in Hzf-deficient mice reflect, at least in part, a direct
or indirect role for Hzf in vWF regulation.
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